Invivyd

Contributing Author

Recent Articles by Invivyd

Jul-02	Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome IVVD GlobeNewswire
Jun-26	Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection IVVD GlobeNewswire
May-27	Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus IVVD GlobeNewswire
May-23	Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas IVVD GlobeNewswire
May-21	Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 IVVD GlobeNewswire
May-15	Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights IVVD GlobeNewswire
May-14	Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy IVVD GlobeNewswire
May-13	Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference IVVD GlobeNewswire
May-12	Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles IVVD GlobeNewswire
May-08	Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 IVVD GlobeNewswire